Euromedica Executive Search successfully appoint Hugh O’Dowd as Independent Board Member for Polyphor AG

London, United Kingdom, 21st April 2021: Euromedica Executive Search are pleased to announce their successful partnership with Polyphor AG (SIX:POLN) to secure Hugh O’Dowd as Independent Board Member, effective 7th April 2021.

Hugh currently serves as independent Non-executive Chairman on the Board of ONK Therapeutics, an innovative natural killer (NK) cell therapy company.

Until its acquisition by BioNTech SE in May 2020, he served for four years as President, Chief Executive Officer and member of the Board of Directors of Neon Therapeutics, Inc. (NASDAQ: NTGN), a clinical- stage immuno-oncology company that developed neoantigen-based therapeutics.

Prior to Neon Therapeutics, Hugh spent more than 20 years in a variety of senior leadership roles at Novartis Pharmaceuticals Corporation including his role as Chief Commercial Officer of Novartis Oncology from 2011 to 2015. During this time, he was responsible for the oncology portfolio strategy for the world’s then second-largest oncology / hematology organization, including global brand leadership, business development/licensing, and commercialization.


For further information regarding Polyphor’s AGM 2021 and the details of Hugh’s appointment, please refer to


About Polyphor AG:

Polyphor is a research driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform.

For more information, visit

Contact us

Get in touch to learn how we can add value to your business or career.